Dan Zheng1,2,3, Feixia Gao1, Cheng Zhao2,3, Yahong Ding1, Yemin Cao2,3, Tianhan Yang1, Xuesong Xu4, Ze Chen1. 1. a Department of Research and Development , Shanghai Institute of Biological Products , Shanghai , China. 2. b Shanghai TCM-Integrated Hospital , Shanghai University of Traditional Chinese Medicine , Shanghai , China. 3. c Department of Vascular Disease , Shanghai TCM-Integrated Institute of Vascular Disease , Shanghai , China. 4. d Huadong Hospital Affiliated to Fudan University , Shanghai , China.
Abstract
BACKGROUND: Avian H7N9 influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity and safety of H7N9 vaccines. METHODS: Database research with defined selection criteria was conducted in PubMed, Cochrane Central Register of Controlled Trials, the World Health Organization's International Clinical Trials Registry Platform, ClinicalTrials.gov, etc. Data from randomized clinical trials regarding the immunogenicity and safety of H7N9 vaccines were collected and meta-analyzed. RESULTS: For non-adjuvanted H7N9 vaccines, high dose formulations induced limited immunogenicity and increased the risk of local and systemic adverse events, simultaneously. For adjuvanted H7N9 vaccines, on the one hand, ISCOMATRIX, MF59, AS03 and aluminium adjuvants applied in H7N9 vaccines could improve immune responses effectively, and non-aluminium adjuvants had superior performance in saving vaccine dose; on the other hand, aluminium adjuvant had the advantages of safety amongst these adjuvants applied in H7N9 vaccines. CONCLUSION: H7N9 influenza vaccines with adjuvant might represent the optimal available option in an influenza pandemic, at present.
BACKGROUND: Avian H7N9influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity and safety of H7N9 vaccines. METHODS: Database research with defined selection criteria was conducted in PubMed, Cochrane Central Register of Controlled Trials, the World Health Organization's International Clinical Trials Registry Platform, ClinicalTrials.gov, etc. Data from randomized clinical trials regarding the immunogenicity and safety of H7N9 vaccines were collected and meta-analyzed. RESULTS: For non-adjuvanted H7N9 vaccines, high dose formulations induced limited immunogenicity and increased the risk of local and systemic adverse events, simultaneously. For adjuvanted H7N9 vaccines, on the one hand, ISCOMATRIX, MF59, AS03 and aluminium adjuvants applied in H7N9 vaccines could improve immune responses effectively, and non-aluminium adjuvants had superior performance in saving vaccine dose; on the other hand, aluminium adjuvant had the advantages of safety amongst these adjuvants applied in H7N9 vaccines. CONCLUSION:H7N9influenza vaccines with adjuvant might represent the optimal available option in an influenza pandemic, at present.
Authors: Milena Apetito Akamatsu; Vitor Anselmo Sakihara; Bianca Pereira Carvalho; Aline de Paiva Abrantes; Maria A Sakauchi Takano; Eduardo Alfredo Adami; Fernando Seiji Yonehara; Patrícia Dos Santos Carneiro; Stefanni Rico; Alessandra Schanoski; Maurício Meros; Adrian Simpson; Tony Phan; Christopher B Fox; Paulo Lee Ho Journal: PLoS One Date: 2020-06-03 Impact factor: 3.240
Authors: Tazio Vanni; Beatriz C Thomé; Erin Sparrow; Martin Friede; Christopher B Fox; Anna Marie Beckmann; Chuong Huynh; Gabriella Mondini; Daniela H Silveira; Juliana Y K Viscondi; Patrícia Emilia Braga; Anderson da Silva; Maria da Graça Salomão; Roberta O Piorelli; Joane P Santos; Vera Lúcia Gattás; Maria Beatriz B Lucchesi; Mayra M M de Oliveira; Marcelo E Koike; Esper G Kallas; Lucia M A Campos; Eduardo B Coelho; Marilda A M Siqueira; Cristiana C Garcia; Milene Dias Miranda; Terezinha M Paiva; Maria do Carmo S T Timenetsky; Eduardo A Adami; Milena A Akamatsu; Paulo Lee Ho; Alexander R Precioso Journal: PLoS One Date: 2022-10-18 Impact factor: 3.752